GlassScriptPhysician profile
Elise J De
NPI 1699855619
$22,453.73
in general payments reported to CMS, 2019-2025
14 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,250 · 2022: $8,498 · 2023: $6,612 · 2024: $3,354 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,000 · Food and Beverage: $1,493 · Travel and Lodging: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,000.00 |
| Food and Beverage | $1,493.10 |
| Travel and Lodging | $212.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Flume Catheter Company INC. | $13,500.00 | 2022-2024 | Flume Catheter |
| Ironwood Pharmaceuticals, INC | $3,625.00 | 2022 | |
| Laborie Medical Technologies Corp. | $3,433.79 | 2021-2023 | |
| Medtronic, INC. | $731.33 | 2022-2025 | Interstim, Altaviva |
| Axonics, INC. | $287.79 | 2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $179.87 | 2022-2023 | Ams 700 Cxr Rte Kit |
| Sumitomo Pharma America, INC. | $166.77 | 2023-2024 | Gemtesa |
| Dendreon Pharmaceuticals LLC | $148.24 | 2025 | Provenge |
| Coloplast Corp | $100.40 | 2025 | |
| Abbvie INC. | $73.67 | 2024-2025 | |
| Urovant Sciences INC | $71.92 | 2022 | |
| 180 Medical, INC. | $68.99 | 2025 | |
| Grt US Holding, INC. | $42.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elise De listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.